-
Mashup Score: 0Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0When to Add ADT to Early or Late Salvage Radiation - Dan Spratt - 2 year(s) ago
Daniel Spratt, MD, reviews the data from two trials that demonstrate the selection of patients for the addition of hormone therapy (ADT) to post-prostatectomy radiation therapy. Dr. Spratt discusses two phase three trials that have evaluated hormonal therapy in the postoperative RP setting with a rising PSA. The RTOG 9601 trial and the GETUG-AFU 16 trial are distinct from each other where the…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
When to add #ADT to early or late salvage radiation. @DrSpratticus @caseccc reviews data from two trials demonstrating the selection of pts for the addition of hormone therapy to post-prostatectomy RT > https://t.co/zDyaNeGBh7 @Decipher_VCYT @ashleyrossmdphd @a_dalpra https://t.co/f5b3DwRe9o
-
-
Mashup Score: 3When to Add ADT to Early or Late Salvage Radiation - Dan Spratt - 2 year(s) ago
Daniel Spratt, MD, reviews the data from two trials that demonstrate the selection of patients for the addition of hormone therapy (ADT) to post-prostatectomy radiation therapy. Dr. Spratt discusses two phase three trials that have evaluated hormonal therapy in the postoperative RP setting with a rising PSA. The RTOG 9601 trial and the GETUG-AFU 16 trial are distinct from each other where the…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
When to add #ADT to early or late salvage radiation. @DrSpratticus @caseccc reviews data from two trials demonstrating the selection of pts for the addition of hormone therapy to post-prostatectomy RT > https://t.co/zDyaNeH96F @Decipher_VCYT @ashleyrossmdphd @a_dalpra https://t.co/R3D8oeZg4l
-
-
Mashup Score: 0When to Add ADT to Early or Late Salvage Radiation - Dan Spratt - 2 year(s) ago
Daniel Spratt, MD, reviews the data from two trials that demonstrate the selection of patients for the addition of hormone therapy (ADT) to post-prostatectomy radiation therapy. Dr. Spratt discusses two phase three trials that have evaluated hormonal therapy in the postoperative RP setting with a rising PSA. The RTOG 9601 trial and the GETUG-AFU 16 trial are distinct from each other where the…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
When to add #ADT to early or late salvage radiation. @DrSpratticus @caseccc reviews data from two trials demonstrating the selection of pts for the addition of hormone therapy to post-prostatectomy RT > https://t.co/zDyaNeGBh7 @Decipher_VCYT @ashleyrossmdphd @a_dalpra https://t.co/02rS0hxV8B
-
-
Mashup Score: 6When to Add ADT to Early or Late Salvage Radiation - Dan Spratt - 2 year(s) ago
Daniel Spratt, MD, reviews the data from two trials that demonstrate the selection of patients for the addition of hormone therapy (ADT) to post-prostatectomy radiation therapy. Dr. Spratt discusses two phase three trials that have evaluated hormonal therapy in the postoperative RP setting with a rising PSA. The RTOG 9601 trial and the GETUG-AFU 16 trial are distinct from each other where the…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
When to add #ADT to early or late salvage radiation. @DrSpratticus @caseccc reviews data from two trials demonstrating the selection of pts for the addition of hormone therapy to post-prostatectomy RT > https://t.co/zDyaNeGBh7 @Decipher_VCYT @ashleyrossmdphd @a_dalpra https://t.co/L7AAujFUuO
-
-
Mashup Score: 1
testosterone levels for men on androgen deprivation therapy, castrate resistant prostate cancer (CRPC), androgen deprivation therapy (ADT), prostate cancer patients on androgen deprivation therapy (ADT), gold standard for testosterone measurement, Liquid chromatography-tandem mass spectrometry.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Variability in testosterone measurement between radioimmunoassay, chemiluminescence assay, and liquid chromatography-tandem mass spectrometry among #ProstateCancer patients on #ADT. #BeyondTheAbstract with @drrajvtiwari @UofT > https://t.co/9LdwFPuMlI @UrolOncol https://t.co/GOFjzFzXZA
-
-
Mashup Score: 1Intensification of androgen deprivation therapy in high-risk, non-metastatic prostate cancer: Lessons from STAMPEDE - PubMed - 2 year(s) ago
Intensification of androgen deprivation therapy in high-risk, non-metastatic prostate cancer: Lessons from STAMPEDE
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
Commentary w/ @CSCancerCare #GUoncology director @EdwinPosadasMD on latest STAMPEDE phase III RCT adding docetaxel to #ADT in high‐risk, M0 prostate cancer. Thank you @RonaldChenMD @JNCI_Now Cancer Spectrum for inviting us to write on this topic #pcsm https://t.co/3To9RVnDTN https://t.co/rtrTvaHCtp
-
-
Mashup Score: 1Darolutamide plus ADT in Metastatic Hormone-Sensitive Prostate Cancer - The ARASEC Trial - Neal Shore - 2 year(s) ago
In this discussion, Neal Shore joins Alicia Morgans in a conversation about a clinical trial for patients with mHSPC, the ARASEC trial. This study is designed to demonstrate how well darolutamide administered together with androgen deprivation therapy works in men with metastatic hormone-sensitive prostate cancer. Biographies: Neal Shore, MD, FACS , is the Medical Director of the Carolina…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Darolutamide plus #ADT in metastatic hormone-sensitive #ProstateCancer. Neal Shore, MD, FRCS @AtlanticUrology joins @CaPsurvivorship @DanaFarber in a discussion on the #ARASEC trial. #WatchNow on UroToday > https://t.co/WYYSkaDvtK @ASCO #GU22 @GenesisCare @Bayer https://t.co/YohbzeorfL
-
-
Mashup Score: 0
testosterone levels for men on androgen deprivation therapy, castrate resistant prostate cancer (CRPC), androgen deprivation therapy (ADT), prostate cancer patients on androgen deprivation therapy (ADT), gold standard for testosterone measurement, Liquid chromatography-tandem mass spectrometry.
Source: www.urotoday.comCategories: Latest Headlines, UrologyTweet-
Variability in testosterone measurement between radioimmunoassay, chemiluminescence assay, and liquid chromatography-tandem mass spectrometry among #ProstateCancer patients on #ADT. #BeyondTheAbstract with @drrajvtiwari @UofT > https://t.co/9LdwFPuMlI @UrolOncol https://t.co/Cv2unGx36F
-
-
Mashup Score: 1Darolutamide plus ADT in Metastatic Hormone-Sensitive Prostate Cancer - The ARASEC Trial - Neal Shore - 2 year(s) ago
In this discussion, Neal Shore joins Alicia Morgans in a conversation about a clinical trial for patients with mHSPC, the ARASEC trial. This study is designed to demonstrate how well darolutamide administered together with androgen deprivation therapy works in men with metastatic hormone-sensitive prostate cancer. Biographies: Neal Shore, MD, FACS , is the Medical Director of the Carolina…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Darolutamide plus #ADT in metastatic hormone-sensitive #ProstateCancer. Neal Shore, MD, FRCS @AtlanticUrology joins @CaPsurvivorship @DanaFarber in a discussion on the #ARASEC trial. #WatchNow on UroToday > https://t.co/WYYSkaV6Sk @ASCO #GU22 @GenesisCare @Bayer https://t.co/zQUlK2wwKG
-
Data from the Phase III ARASENS trial showed darolutamide plus #ADT and docetaxel led to an overall #survival benefit over placebo plus ADT and docetaxel in Black/African American patients with metastatic hormone-sensitive #ProstateCancer #mHSPC: https://t.co/ShKggTj3N5 https://t.co/WTYKppZtKF